Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Goodwill & Intangibles (2022 - 2025)

Neurocrine Biosciences' Goodwill & Intangibles history spans 4 years, with the latest figure at $35.7 million for Q3 2025.

  • For Q3 2025, Goodwill & Intangibles fell 12.07% year-over-year to $35.7 million; the TTM value through Sep 2025 reached $35.7 million, down 12.07%, while the annual FY2024 figure was $42.2 million, 2.18% up from the prior year.
  • Goodwill & Intangibles reached $35.7 million in Q3 2025 per NBIX's latest filing, down from $37.2 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $42.8 million in Q1 2023 to a low of $35.7 million in Q3 2025.
  • Average Goodwill & Intangibles over 4 years is $40.1 million, with a median of $40.5 million recorded in 2023.
  • Peak YoY movement for Goodwill & Intangibles: grew 2.18% in 2024, then decreased 12.07% in 2025.
  • A 4-year view of Goodwill & Intangibles shows it stood at $42.6 million in 2022, then dropped by 3.05% to $41.3 million in 2023, then increased by 2.18% to $42.2 million in 2024, then dropped by 15.4% to $35.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Goodwill & Intangibles are $35.7 million (Q3 2025), $37.2 million (Q2 2025), and $36.4 million (Q1 2025).